File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells

TitleGalectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells
Authors
KeywordsGalectin-1
Hepatocellular carcinoma
miR-22
Therapeutics
OTX008
Issue Date2019
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.jeccr.com/home
Citation
Journal of Experimental and Clinical Cancer Research, 2019, v. 38, article no. 423 How to Cite?
AbstractBackground: Galectins are beta-galactose specific binding proteins. In human cancers, including hepatocellular carcinoma (HCC), galectin-1 (Gal-1) is often found to be overexpressed. In order to combat the dismal diagnosis and death rates of HCC, gene silencing and targeted inhibition of Gal-1 was investigated for its improved therapeutic potential. Methods: Cellular and secretory Gal-1 levels were analyzed using HCC clinical samples. The study of Gal-1 was carried by both knockdown and overexpression approaches. The stable clones were tested by in vitro assays and in vivo experiments. Mass spectrometry was used to identify downstream targets of Gal-1. The upstream regulator of Gal-1, microRNA-22 (miR-22) was characterized by functional assays. The therapeutic effect of inhibiting Gal-1 was also analyzed. Results: Gal-1 overexpression was observed in HCC and correlated with aggressive clinicopathological features and poorer survival. The loss of Gal-1 resulted in hindered cell migration, invasion and anchorage independent growth. This was also observed in the animal models, in that when Gal-1 was knocked down, there were fewer lung metastases. Proteomic profiling of control and Gal-1 knockdown cells identified that the level of retention in endoplasmic reticulum 1 (RER1) was suppressed when Gal-1 level was reduced. The cell motility of Gal-1 knockdown cells was enhanced upon the rescue of RER1 expression. In HCC tissues, Gal-1 and RER1 expressions displayed a significant positive correlation. The upstream regulator of Gal-1, miR-22 was observed to be underexpressed in HCC tissues and negatively correlated with Gal-1. Silencing of miR-22 resulted in the upregulation of Gal-1 and enhanced cell growth, migration and invasion. However, such enhancement was abolished in cells treated with OTX008, an inhibitor of Gal-1. Combinational treatment of OTX008 and sorafenib significantly reduced tumor growth and size. Conclusions: Gal-1 overexpression was detected in HCC and this played a role in promoting tumorigenic processes and metastasis. The function of Gal-1 was found to be mediated through RER1. The correlations between miR-22, Gal-1 and RER1 expressions demonstrated the importance of miR-22 regulation on Gal-1/RER1 oncogenic activity. Lastly, the combinational treatment of OTX008 and sorafenib proved to be an improved therapeutic option compared to when administering sorafenib alone.
Persistent Identifierhttp://hdl.handle.net/10722/274833
ISSN
2018 Impact Factor: 5.646
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorLeung, Z-
dc.contributor.authorKo, FCF-
dc.contributor.authorTey, SK-
dc.contributor.authorKwong, EML-
dc.contributor.authorMao, X-
dc.contributor.authorLiu, BHM-
dc.contributor.authorMa, APY-
dc.contributor.authorFung, YME-
dc.contributor.authorChe, C-M-
dc.contributor.authorWong, DKH-
dc.contributor.authorLai, CL-
dc.contributor.authorNg, IO-L-
dc.contributor.authorYam, JWP-
dc.date.accessioned2019-09-10T02:29:46Z-
dc.date.available2019-09-10T02:29:46Z-
dc.date.issued2019-
dc.identifier.citationJournal of Experimental and Clinical Cancer Research, 2019, v. 38, article no. 423-
dc.identifier.issn1756-9966-
dc.identifier.urihttp://hdl.handle.net/10722/274833-
dc.description.abstractBackground: Galectins are beta-galactose specific binding proteins. In human cancers, including hepatocellular carcinoma (HCC), galectin-1 (Gal-1) is often found to be overexpressed. In order to combat the dismal diagnosis and death rates of HCC, gene silencing and targeted inhibition of Gal-1 was investigated for its improved therapeutic potential. Methods: Cellular and secretory Gal-1 levels were analyzed using HCC clinical samples. The study of Gal-1 was carried by both knockdown and overexpression approaches. The stable clones were tested by in vitro assays and in vivo experiments. Mass spectrometry was used to identify downstream targets of Gal-1. The upstream regulator of Gal-1, microRNA-22 (miR-22) was characterized by functional assays. The therapeutic effect of inhibiting Gal-1 was also analyzed. Results: Gal-1 overexpression was observed in HCC and correlated with aggressive clinicopathological features and poorer survival. The loss of Gal-1 resulted in hindered cell migration, invasion and anchorage independent growth. This was also observed in the animal models, in that when Gal-1 was knocked down, there were fewer lung metastases. Proteomic profiling of control and Gal-1 knockdown cells identified that the level of retention in endoplasmic reticulum 1 (RER1) was suppressed when Gal-1 level was reduced. The cell motility of Gal-1 knockdown cells was enhanced upon the rescue of RER1 expression. In HCC tissues, Gal-1 and RER1 expressions displayed a significant positive correlation. The upstream regulator of Gal-1, miR-22 was observed to be underexpressed in HCC tissues and negatively correlated with Gal-1. Silencing of miR-22 resulted in the upregulation of Gal-1 and enhanced cell growth, migration and invasion. However, such enhancement was abolished in cells treated with OTX008, an inhibitor of Gal-1. Combinational treatment of OTX008 and sorafenib significantly reduced tumor growth and size. Conclusions: Gal-1 overexpression was detected in HCC and this played a role in promoting tumorigenic processes and metastasis. The function of Gal-1 was found to be mediated through RER1. The correlations between miR-22, Gal-1 and RER1 expressions demonstrated the importance of miR-22 regulation on Gal-1/RER1 oncogenic activity. Lastly, the combinational treatment of OTX008 and sorafenib proved to be an improved therapeutic option compared to when administering sorafenib alone.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.jeccr.com/home-
dc.relation.ispartofJournal of Experimental and Clinical Cancer Research-
dc.rightsJournal of Experimental and Clinical Cancer Research. Copyright © BioMed Central Ltd.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectGalectin-1-
dc.subjectHepatocellular carcinoma-
dc.subjectmiR-22-
dc.subjectTherapeutics-
dc.subjectOTX008-
dc.titleGalectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells-
dc.typeArticle-
dc.identifier.emailKo, FCF: bokcf@hku.hk-
dc.identifier.emailTey, SK: szekeong@hku.hk-
dc.identifier.emailKwong, ML: ernest18@hku.hk-
dc.identifier.emailMao, X: susanmao@hku.hk-
dc.identifier.emailFung, EYM: eva.fungym@hku.hk-
dc.identifier.emailChe, CM: chemhead@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.emailNg, IOL: iolng@hku.hk-
dc.identifier.emailYam, JWP: jywp@hkucc.hku.hk-
dc.identifier.authorityFung, EYM=rp01986-
dc.identifier.authorityChe, CM=rp00670-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityNg, IOL=rp00335-
dc.identifier.authorityYam, JWP=rp00468-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s13046-019-1402-x-
dc.identifier.pmid31640796-
dc.identifier.pmcidPMC6805403-
dc.identifier.scopuseid_2-s2.0-85073749198-
dc.identifier.hkuros305028-
dc.identifier.hkuros305031-
dc.identifier.hkuros309599-
dc.identifier.volume38-
dc.identifier.spagearticle no. 423(2019)-
dc.identifier.epagearticle no. 423(2019)-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats